These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28250257)

  • 1. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.
    Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M
    Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows.
    Krüger M; Skau M; Shehata AA; Schrödl W
    Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Clostridium botulinum type C antitoxin titers in mink and guinea pigs to protection against type C intoxication in mink.
    Kolbe DR; Coe Clough NE
    Anaerobe; 2008 Apr; 14(2):128-30. PubMed ID: 18032073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid.
    Torii Y; Tokumaru Y; Kawaguchi S; Izumi N; Maruyama S; Mukamoto M; Kozaki S; Takahashi M
    Vaccine; 2002 Jun; 20(19-20):2556-61. PubMed ID: 12057613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
    Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved method for development of toxoid vaccines and antitoxins.
    Jones RG; Liu Y; Rigsby P; Sesardic D
    J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin vaccines: Past history and recent developments.
    Rusnak JM; Smith LA
    Hum Vaccin; 2009 Dec; 5(12):794-805. PubMed ID: 19684478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.
    Keller JE
    Clin Vaccine Immunol; 2008 Sep; 15(9):1374-9. PubMed ID: 18667637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum neurotoxin vaccines: past, present, and future.
    Smith LA; Rusnak JM
    Crit Rev Immunol; 2007; 27(4):303-18. PubMed ID: 18197811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.
    Siegel LS
    J Clin Microbiol; 1989 Aug; 27(8):1906-8. PubMed ID: 2768475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
    Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
    Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward development of an inhalation vaccine against botulinum toxin.
    Park JB; Simpson LL
    Expert Rev Vaccines; 2004 Aug; 3(4):477-87. PubMed ID: 15270652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers.
    Edelman R; Wasserman SS; Bodison SA; Perry JG; O'Donnoghue M; DeTolla LJ
    Vaccine; 2003 Oct; 21(27-30):4335-47. PubMed ID: 14505916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.
    Pittman PR; Hack D; Mangiafico J; Gibbs P; McKee KT; Friedlander AM; Sjogren MH
    Vaccine; 2002 May; 20(16):2107-15. PubMed ID: 11972980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulism and vaccines for its prevention.
    Smith LA
    Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.